These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 27284419)

  • 1. Poor efficacy of the phosphorylated high-molecular-weight neurofilament heavy subunit serum level, a biomarker of axonal damage, as a marker of chemotherapy-induced peripheral neuropathy.
    Sumitani M; Ogata T; Natori A; Hozumi J; Shimojo N; Kida K; Yamauchi H; Yamauchi T
    Biomed Rep; 2016 Jun; 4(6):758-760. PubMed ID: 27284419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential role of pNF-H, a biomarker of axonal damage in the central nervous system, as a predictive marker of chemotherapy-induced cognitive impairment.
    Natori A; Ogata T; Sumitani M; Kogure T; Yamauchi T; Yamauchi H
    Clin Cancer Res; 2015 Mar; 21(6):1348-52. PubMed ID: 25589615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct evidence of central nervous system axonal damage in patients with postoperative delirium: A preliminary study of pNF-H as a promising serum biomarker.
    Inoue R; Sumitani M; Ogata T; Chikuda H; Matsubara T; Kato S; Shimojo N; Uchida K; Yamada Y
    Neurosci Lett; 2017 Jul; 653():39-44. PubMed ID: 28504118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dysfunction of the blood-brain barrier in postoperative delirium patients, referring to the axonal damage biomarker phosphorylated neurofilament heavy subunit.
    Mietani K; Sumitani M; Ogata T; Shimojo N; Inoue R; Abe H; Kawamura G; Yamada Y
    PLoS One; 2019; 14(10):e0222721. PubMed ID: 31574089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphorylated neurofilament subunit levels in the serum of cervical compressive myelopathy patients.
    Kato S; Chikuda H; Ohya J; Hayakawa K; Takeshita K; Tanaka S; Ogata T
    J Clin Neurosci; 2015 Oct; 22(10):1638-42. PubMed ID: 26195334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Objective evaluation of chemotherapy-induced peripheral neuropathy using quantitative pain measurement system (Pain Vision
    Sato J; Mori M; Nihei S; Takeuchi S; Kashiwaba M; Kudo K
    J Pharm Health Care Sci; 2017; 3():21. PubMed ID: 28770097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomised, placebo-controlled trial assessing the efficacy of an oral B group vitamin in preventing the development of chemotherapy-induced peripheral neuropathy (CIPN).
    Schloss JM; Colosimo M; Airey C; Masci P; Linnane AW; Vitetta L
    Support Care Cancer; 2017 Jan; 25(1):195-204. PubMed ID: 27612466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphorylated neurofilament heavy subunit (pNF-H) in peripheral blood and CSF as a potential prognostic biomarker in amyotrophic lateral sclerosis.
    Boylan KB; Glass JD; Crook JE; Yang C; Thomas CS; Desaro P; Johnston A; Overstreet K; Kelly C; Polak M; Shaw G
    J Neurol Neurosurg Psychiatry; 2013 Apr; 84(4):467-72. PubMed ID: 23117489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The evaluation of changes in peripheral neuropathy and quality-of-life using low-frequency electrostimulation in patients treated with chemotherapy for breast cancer: a study protocol.
    Jang CE; Jung MS; Sohn EH; Kim M; Yoo HS; Bae K; Kim JR; Lee JS
    Trials; 2018 Sep; 19(1):526. PubMed ID: 30268158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective surveillance model for physical rehabilitation of women with breast cancer: chemotherapy-induced peripheral neuropathy.
    Stubblefield MD; McNeely ML; Alfano CM; Mayer DK
    Cancer; 2012 Apr; 118(8 Suppl):2250-60. PubMed ID: 22488699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS).
    Binda D; Vanhoutte EK; Cavaletti G; Cornblath DR; Postma TJ; Frigeni B; Alberti P; Bruna J; Velasco R; Argyriou AA; Kalofonos HP; Psimaras D; Ricard D; Pace A; Galiè E; Briani C; Dalla Torre C; Lalisang RI; Boogerd W; Brandsma D; Koeppen S; Hense J; Storey D; Kerrigan S; Schenone A; Fabbri S; Rossi E; Valsecchi MG; Faber CG; Merkies IS; ; Galimberti S; Lanzani F; Mattavelli L; Piatti ML; Bidoli P; Cazzaniga M; Cortinovis D; Lucchetta M; Campagnolo M; Bakkers M; Brouwer B; Boogerd W; Grant R; Reni L; Piras B; Pessino A; Padua L; Granata G; Leandri M; Ghignotti I; Plasmati R; Pastorelli F; Heimans JJ; Eurelings M; Meijer RJ; Grisold W; Lindeck Pozza E; Mazzeo A; Toscano A; Russo M; Tomasello C; Altavilla G; Penas Prado M; Dominguez Gonzalez C; Dorsey SG
    Eur J Cancer; 2013 Sep; 49(13):2910-8. PubMed ID: 23668917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuropathic Pain and Nerve Growth Factor in Chemotherapy-Induced Peripheral Neuropathy: Prospective Clinical-Pathological Study.
    Velasco R; Navarro X; Gil-Gil M; Herrando-Grabulosa M; Calls A; Bruna J
    J Pain Symptom Manage; 2017 Dec; 54(6):815-825. PubMed ID: 28797868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk.
    Bao T; Basal C; Seluzicki C; Li SQ; Seidman AD; Mao JJ
    Breast Cancer Res Treat; 2016 Sep; 159(2):327-33. PubMed ID: 27510185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of Mirogabalin and Duloxetine Attenuates Peripheral Neuropathy by Eribulin: A Novel Case Report.
    Saito Y; Takekuma Y; Oshino T; Sugawara M
    Case Rep Oncol; 2022; 15(2):606-610. PubMed ID: 35949911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating the impact of chemotherapy-induced peripheral neuropathy symptoms (CIPN-sx) on perceived ability to work in breast cancer survivors during the first year post-treatment.
    Zanville NR; Nudelman KN; Smith DJ; Von Ah D; McDonald BC; Champion VL; Saykin AJ
    Support Care Cancer; 2016 Nov; 24(11):4779-89. PubMed ID: 27470258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Association of Chemotherapy-Induced Peripheral Neuropathy Symptoms and the Risk of Falling.
    Kolb NA; Smith AG; Singleton JR; Beck SL; Stoddard GJ; Brown S; Mooney K
    JAMA Neurol; 2016 Jul; 73(7):860-6. PubMed ID: 27183099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serial changes in serum phosphorylated neurofilament and value for prediction of clinical outcome after traumatic brain injury.
    Otani N; Morimoto Y; Kinoshita M; Ogata T; Mori K; Kobayashi M; Maeda T; Yoshino A
    Surg Neurol Int; 2020; 11():387. PubMed ID: 33408921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebral Perfusion and Gray Matter Changes Associated With Chemotherapy-Induced Peripheral Neuropathy.
    Nudelman KN; McDonald BC; Wang Y; Smith DJ; West JD; O'Neill DP; Zanville NR; Champion VL; Schneider BP; Saykin AJ
    J Clin Oncol; 2016 Mar; 34(7):677-83. PubMed ID: 26527786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Mechanistic Understanding of Axon Degeneration in Chemotherapy-Induced Peripheral Neuropathy.
    Fukuda Y; Li Y; Segal RA
    Front Neurosci; 2017; 11():481. PubMed ID: 28912674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial.
    Kleckner IR; Kamen C; Gewandter JS; Mohile NA; Heckler CE; Culakova E; Fung C; Janelsins MC; Asare M; Lin PJ; Reddy PS; Giguere J; Berenberg J; Kesler SR; Mustian KM
    Support Care Cancer; 2018 Apr; 26(4):1019-1028. PubMed ID: 29243164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.